Profile data is unavailable for this security.
About the company
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company. It is focused on translating insights from genetic epilepsies into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, is an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. Its product candidates include ulixacaltamide, PRAX-562, PRAX-628 and elsunersen.
- Revenue in USD (TTM)2.45m
- Net income in USD-123.28m
- Incorporated2015
- Employees82.00
- LocationPraxis Precision Medicines Inc99 High Street, 30th FloorBOSTON 02110United StatesUSA
- Phone+1 (617) 300-8460
- Fax+1 (302) 655-5049
- Websitehttps://praxismedicines.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPKO Health Inc | 863.49m | -188.86m | 906.09m | 3.93k | -- | 0.7236 | -- | 1.05 | -0.2513 | -0.2513 | 1.15 | 1.80 | 0.4133 | 7.80 | 6.89 | 219,718.60 | -9.03 | -7.14 | -10.03 | -8.14 | 36.84 | 34.42 | -21.86 | -13.83 | 1.22 | -15.24 | 0.1574 | -- | -14.01 | -2.70 | 42.49 | -- | -10.19 | -- |
| BioCryst Pharmaceuticals Inc | 331.41m | -226.54m | 918.17m | 536.00 | -- | -- | -- | 2.77 | -1.18 | -1.18 | 1.72 | -2.21 | 0.6212 | 0.1658 | 6.16 | 618,306.00 | -42.46 | -47.95 | -55.84 | -64.89 | 98.59 | 97.06 | -68.36 | -114.94 | 3.12 | -1.11 | 2.19 | -- | 22.37 | 74.21 | 8.33 | -- | 42.73 | -- |
| Arcutis Biotherapeutics Inc | 59.61m | -262.14m | 924.20m | 296.00 | -- | 8.73 | -- | 15.51 | -3.90 | -3.90 | 0.8602 | 0.9161 | 0.1508 | 0.483 | 3.48 | 201,371.60 | -66.31 | -65.64 | -74.24 | -71.72 | 91.63 | -- | -439.79 | -1,513.03 | 6.80 | -8.11 | 0.6947 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
| Relay Therapeutics Inc | 35.33m | -329.12m | 931.64m | 309.00 | -- | 1.25 | -- | 26.37 | -2.64 | -2.64 | 0.2841 | 5.64 | 0.0376 | -- | -- | 109,371.50 | -35.03 | -28.55 | -37.16 | -29.54 | -- | -- | -931.64 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
| Praxis Precision Medicines Inc | 2.45m | -123.28m | 933.06m | 82.00 | -- | 6.88 | -- | 381.31 | -23.64 | -23.64 | 0.3719 | 7.92 | 0.0241 | -- | -- | 29,841.46 | -121.41 | -74.04 | -161.17 | -85.12 | -- | -- | -5,037.88 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
| Bicycle Therapeutics PLC (ADR) | 41.61m | -168.16m | 933.24m | 284.00 | -- | -- | -- | 22.43 | -4.45 | -4.45 | 1.08 | -- | -- | -- | -- | 146,514.10 | -- | -29.45 | -- | -32.98 | -- | -- | -404.14 | -571.36 | -- | -- | -- | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
| Tyra Biosciences Inc | 0.00 | -69.13m | 937.55m | 49.00 | -- | 3.76 | -- | -- | -1.62 | -1.62 | 0.00 | 4.75 | 0.00 | -- | -- | 0.00 | -28.10 | -- | -29.36 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
| Immunome Inc | 14.02m | -106.81m | 944.11m | 55.00 | -- | 5.68 | -- | 67.35 | -3.33 | -3.33 | 0.7064 | 2.77 | 0.1625 | -- | -- | 254,872.70 | -123.77 | -94.54 | -148.94 | -112.66 | -- | -- | -761.92 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
| ARS Pharmaceuticals Inc | 30.00k | -54.37m | 944.72m | 24.00 | -- | 4.07 | -- | 31,490.68 | -0.5719 | -0.5719 | 0.0003 | 2.39 | 0.0001 | -- | -- | 1,250.00 | -21.13 | -20.37 | -21.45 | -21.32 | -- | -- | -181,216.70 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
| Cassava Sciences Inc | 0.00 | -97.22m | 953.57m | 29.00 | -- | 6.77 | -- | -- | -2.32 | -2.32 | 0.00 | 3.25 | 0.00 | -- | -- | 0.00 | -50.31 | -30.74 | -53.23 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
| Ocular Therapeutix Inc | 58.44m | -80.74m | 954.66m | 267.00 | -- | 7.78 | -- | 16.34 | -0.9939 | -0.9939 | 0.7233 | 0.7927 | 0.2912 | 2.47 | 2.46 | 218,883.90 | -40.23 | -46.70 | -48.19 | -54.18 | 90.96 | 89.36 | -138.15 | -228.65 | 6.59 | -6.57 | 0.4512 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
| Innoviva Inc | 310.46m | 179.72m | 961.06m | 112.00 | 6.78 | 1.43 | 4.46 | 3.10 | 2.24 | 2.24 | 3.96 | 10.66 | 0.2509 | 0.8825 | 4.19 | 2,771,991.00 | 14.52 | 26.24 | 15.62 | 28.53 | 86.27 | -- | 57.89 | 76.84 | 7.96 | -- | 0.398 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
| Liquidia Corp | 17.49m | -78.50m | 972.40m | 136.00 | -- | 18.56 | -- | 55.60 | -1.21 | -1.21 | 0.2691 | 0.6891 | 0.1413 | -- | 3.85 | 128,588.20 | -63.43 | -55.02 | -71.31 | -62.69 | 83.49 | 82.18 | -448.89 | -474.59 | -- | -26.14 | 0.4942 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
| MacroGenics Inc | 58.75m | -9.06m | 980.32m | 339.00 | -- | 6.37 | 1,672.91 | 16.69 | -0.1525 | -0.1525 | 0.9462 | 2.46 | 0.203 | 6.15 | 1.76 | 173,300.90 | -3.13 | -37.76 | -3.82 | -45.53 | 86.00 | -- | -15.42 | -133.96 | 4.46 | -117.57 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
| Viridian Therapeutics Inc | 314.00k | -237.73m | 982.87m | 96.00 | -- | 3.53 | -- | 3,130.15 | -5.32 | -5.32 | 0.007 | 8.19 | 0.0007 | -- | 3.08 | 3,340.43 | -51.37 | -55.59 | -54.93 | -60.32 | -- | -- | -75,711.47 | -5,678.12 | -- | -- | 0.0437 | -- | -82.28 | -48.16 | -83.05 | -- | 15.08 | -- |
Data as of May 03 2024. Currency figures normalised to Praxis Precision Medicines Inc's reporting currency: US Dollar USD
39.11%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Point72 Asset Management LPas of 31 Dec 2023 | 758.19k | 5.73% |
| Adage Capital Management LPas of 31 Dec 2023 | 738.67k | 5.58% |
| Verition Fund Management LLCas of 31 Dec 2023 | 703.00k | 5.31% |
| PFM Health Sciences LPas of 31 Dec 2023 | 656.55k | 4.96% |
| Cormorant Asset Management LPas of 31 Dec 2023 | 633.35k | 4.78% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 366.24k | 2.77% |
| Kingdon Capital Management LLCas of 31 Dec 2023 | 346.67k | 2.62% |
| Velan Capital Investment Management LPas of 31 Dec 2023 | 345.67k | 2.61% |
| Sphera Funds Management Ltd.as of 31 Dec 2023 | 328.99k | 2.49% |
| Acuta Capital Partners LLCas of 31 Dec 2023 | 299.64k | 2.26% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
